US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase ...

RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, ...

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...